Non Hodgkin's Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Leukemia
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    N
    Recruiting
    • Myelodysplastic Syndrome
    • +4 more
    • Rituximab
    • +6 more
    • Bethesda, Maryland
    • +1 more
    2022-04-07
    Apr 7, 2022
    N
    Recruiting
    • Non-Hodgkin's Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    N
    Recruiting
    • Follicular Lymphoma
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    E
    Completed
    • Advanced Cancer
    • +5 more
    • Los Angeles, California
    • +7 more
    2022-04-07
    Apr 7, 2022
    O
    Recruiting
    • Acute Lymphoblastic Leukemia
    • +2 more
    • CLIC-1901
    • Vancouver, British Columbia, Canada
    • +1 more
    2022-03-26
    Mar 26, 2022
    N
    Completed
    • Chronic Myelogenous Leukemia
    • +9 more
    • Atlanta, Georgia
      Northside Hospital
    2022-04-04
    Apr 4, 2022
    A
    Active, not recruiting
    • CD20-Positive Lymphoid Malignancies
    • +3 more
    • Tucson, Arizona
    • +5 more
    2022-03-22
    Mar 22, 2022
    L
    Recruiting
    • Non-Hodgkin's Lymphoma
    • RiTUXimab Injection [Truxima]
    • Vitoria-Gasteiz, Alava, Spain
      Hospital Universitario Araba- Sede Txagorritxu
    2022-03-30
    Mar 30, 2022
    A
    Recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Phoenix, Arizona
    • +30 more
    2022-03-28
    Mar 28, 2022
    S
    Terminated
    • Acute Myelogenous Leukemia
    • +2 more
    • Oklahoma City, Oklahoma
    • +1 more
    2022-03-17
    Mar 17, 2022
    A
    Available
    • Chronic Lymphocytic Leukemia (CLL)
    • +6 more
    • (no location specified)
    2022-03-28
    Mar 28, 2022
    U
    Active, not recruiting
    • Non-Hodgkin's Lymphoma
    • Hodgkin's Lymphoma
    • CAR.CD30 T cells
    • Chapel Hill, North Carolina
    • +2 more
    2022-03-16
    Mar 16, 2022
    C
    Completed
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    2022-03-07
    Mar 7, 2022
    M
    Recruiting
    • Diffuse Large B-cell Lymphoma
    • +2 more
    • Buffalo, New York
    • +3 more
    2022-03-01
    Mar 1, 2022
    J
    Recruiting
    • Non-Hodgkin's Lymphoma
    • single dose of CNCT19
    • Fuzhou, Fujian, China
    • +17 more
    2022-02-17
    Feb 17, 2022
    B
    Active, not recruiting
    • Non-Hodgkin's Lymphoma
    • +2 more
    • Nivolumab
    • +5 more
    • Clovis, California
    • +30 more
    2022-01-27
    Jan 27, 2022
    B
    Recruiting
    • Non-Hodgkin's Lymphoma
    • +2 more
    • CD19.CAR-CD28Z T Cells - dose escalation 2
    • CD19.CAR-CD28Z T Cells - dose escalation 1
    • Houston, Texas
    • +1 more
    2022-02-10
    Feb 10, 2022
    B
    Active, not recruiting
    • Hodgkin's Lymphoma
    • Non-Hodgkin's Lymphoma
    • autologous CAR.CD30 EBV specific-CTLs
    • Houston, Texas
    • +1 more
    2022-02-04
    Feb 4, 2022
    H
    Recruiting
    • Non-hodgkin's Lymphoma
    • CD19+22 CAR-T cells
    • Langfang, Hebei, China
      Hebei Yanda Ludaopei Hospital
    2022-01-11
    Jan 11, 2022
    M
    Active, not recruiting
    • Leukemia
    • +3 more
    • Palifermin
    • +6 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    2022-01-21
    Jan 21, 2022